ATS View
한국어

HBL KRX:452190KOSDAQ

한빛레이저 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked13since Sep 11

In Q2 2026, HBL reported revenue of ₩4.5bn, down 44.8% year on year, and operating profit of ₩509m. HBL (한빛레이저) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 20 with 2 articles. It was most often mentioned alongside Isu Specialty Chemical, D&D Pharmatech and HanJungNCS.

HBL quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩4.5bn-44.8%₩509m
margin 11.4%		₩472m
Q1 2026₩6.3bn+690.5%₩171m
margin 2.7%		₩307m
Q4 2025 derived₩10.2bn+33.6%₩2.6bn
margin 25.5%		₩2.9bn
Q3 2025₩5.2bn+14.4%−₩337m
margin −6.5%		−₩164m
Q2 2025₩8.1bn+153.2%₩929m
margin 11.5%		₩944m
Q1 2025₩800m-74.9%−₩1.2bn
margin −153.5%		−₩1.2bn
Q4 2024 derived₩7.6bn-32.3%−₩998m
margin −13.1%		−₩1.4bn
Q3 2024₩4.5bn+40.3%−₩623m
margin −13.8%		−₩455m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

HBL top stories 2 weeks, by number of outlets

  1. 1
    [여의도 투자본부 2부] 한중엔시에스 vs 한빛레이저 vs 디앤디파마텍 vs 이수스페셜티케미컬, 공략법은?
    2 outlets · 2 articlesFirst report Oct 20 06:50 MTNHanJungNCSD&D PharmatechIsu Specialty Chemical

Latest HBL news Korean headlines